glp-1 and alcohol side effects RAs may reduce alcohol-related hospitalization risk Emerging pharmacological targets for alcohol

EMA U.S

Not for human consumption, medical treatment, or veterinary use

Because of their glucose lowering effects, therapies that enhance incretin actions through inhibiting degradation of endogenous incretins or through activation of the GLP-1 receptor are now in use for the treatment of type 2 diabetes ( ATP channels and in postprandial hypoglycemia after gastrointestinal surgery, where the delivery of nutrients to the small intestine is altered resulting in both hyperglycemia and an exaggerated secretion of GLP-1

Glucagon receptor agonism Glucagon receptor activation increases energy expenditure, improves liver health, and promotes fat breakdown